Evidence Level
High Evidence
Mechanism of Action
Selective GLP-1 receptor agonist. Slows gastric emptying, suppresses glucagon, enhances glucose-dependent insulin secretion.
Published Research Ranges & Study Context
Studies have administered: 0.25–2.4mg weekly (STEP trials)
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
STEP 1 trial: 14.9% mean weight reduction vs 2.4% placebo at 68 weeks. SELECT trial showed 20% reduction in major cardiovascular events.
High Evidence
Multiple large human RCTs available
Side Effects Observed in Research
Nausea (44%), diarrhea (30%), vomiting (24%) in STEP trials; mostly mild-moderate
Available Configurations (SKU Reference)
SM5
SM10
SM15
SM20
SM30
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on Semaglutide — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.